Rezolute appoints Erik Harris to board of directors effective March 25, 2025

Rezolute, Inc.

Erik Harris elected to board effective March 25, 2025; determined independent under Nasdaq rules.
Harris is CCO and EVP at Ultragenyx Pharmaceutical since June 2019; previously VP at InterMune, Crescendo Bioscience.
Will receive standard non-employee director cash retainer (pro-rated) and 60,000 stock options at $2.89 exercise price.
Options vest monthly from March 25, 2025, expiring March 25, 2035; committee assignments pending.
No family relationships with directors/officers and no material interest in transactions required to disclose.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erik Harris

Director

RZLT · Rezolute, Inc.

Effective: 2025-03-25
Filed: March 28, 2025, 7:59 PM ET

On March 25, 2025, the Board of Directors (the “Board”) of Rezolute, Inc. (the “Company”) upon the recommendation of the Company’s nominating and corporate governance committee elected Erik Harris to the Board, effective March 25, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Harris was elected as Director at Rezolute, Inc..

Action: elected
Role: Director

Exact text from the filing

On March 25, 2025, the Board of Directors (the “Board”) of Rezolute, Inc. (the “Company”) upon the recommendation of the Company’s nominating and corporate governance committee elected Erik Harris to the Board, effective March 25, 2025

View on SEC.gov

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-029429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.